KONINKLIJKE PHILIPS NV
In the published model solve dated 2026-Q2, anchored at $26.57, KONINKLIJKE PHILIPS NV (PHG) is priced for +8.9% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 28, 2026 from SEC EDGAR filings.
• Philips is a global health-technology company spanning diagnostic imaging, patient monitoring, and personal health products, now run as a focused medical business after years of reshaping its portfolio. • The dominant overhang is the Respironics recall, which cost the company a roughly 1 billion euro cash payment for settlements in the latest year, with a US Department of Justice investigation still open and excluded from guidance. • The recovery is real but partial: reported profitability rem
Is PHG overvalued? See what's priced in →
336 institutional managers reported holding PHG in 13F filings for the quarter ended 2026-03-31. Together they hold about 5% of the company; the top 10 hold 3%. 49 opened new positions that quarter. Held by Dimensional Fund Advisors, Morgan Stanley, FMR (Fidelity), among others. On the short side, 1.7M shares were sold short as of the 2026-06-15 count, about 0.2% of shares outstanding (1.3 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
PHG's share count grew 4.9% over the past five years. It pays a dividend, and has for 7 years running. Cash returned over the past three years: $469.57M in dividends.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 28, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.